Health Condition 1: R739- Hyperglycemia, unspecified Health Condition 2: Z940- Kidney transplant status Health Condition 3: E138- Other specified diabetes mellituswith unspecified complications Health Condition 4: E116- Type 2 diabetes mellitus with other specified complications Health Condition 5: E118- Type 2 diabetes mellitus with unspecified complications
Conditions
Sponsors
CareOps Solutions Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years or older. 2. Undergoing kidney transplant and admitted to the postoperative intensive care unit (ICU). 3. Diagnosed with: Pre-existing diabetes mellitus (type 2), or New-onset hyperglycemia during their ICU stay (defined as blood glucose levels greater that 180 mg dl on two or more occasions). 4. Expected to remain in the ICU for at least 4 5 days postoperatively. 5. Able to provide informed consent or have a legally authorized representative provide consent on their behalf.
Exclusion criteria
Exclusion criteria: Participants will be excluded from the study if they meet any of the following criteria: Diagnosed with type 1 diabetes mellitus or other forms of diabetes requiring specialized insulin regimens. Unable/ unwilling to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Improvement in glycemic control, measured as the percentage of blood glucose readings within the target range (e.g., 70 180 mg/dL). 2. Mean blood glucose Timepoint: 4 5 days of ICU stay. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reduction in hypoglycemic episodes (blood glucose less than 70 mg/dL). 2. Reduction in severe hyperglycemia (blood glucose greater than 250 mg/dL). 3. Impact on length of hospital stay and overall patient outcomes. 4. Reduction in insulin-related dosing errors. 5. Clinician and nursing staff satisfaction with the use of INSULIN-Rx. Timepoint: 4 5 days of ICU stay | — |
Countries
India
Contacts
Public ContactDr Shyam B Bansal
Medanta, the Medicity
Outcome results
None listed